Presentation of the ongoing Clinical Phase II trial at the AACR Virtual Annual Meeting

On April 27th CMO Peter Michael Vestlev will present at the AACR Virtual Annual Meeting. The presentation is a 5 minutes video entitled "Clinical phase II study of SCO-101 - an inhibitor of SRPK1 and ABCG2 - restoring sensitivity to FOLFIRI in metastatic FOLFIRI resistant colorectal cancer patients"

The AACR Virtual Annual Meeting will feature a selection of high-impact proffered paper presentations. The program will include a number of clinical trial plenary sessions featuring more than 30 oral presentations along with perspectives on the science behind the clinical trials by experts discussants; clinical trial poster sessions; several minisymposia that showcase basic and translational science; and three New Drugs on the Horizon symposia that include first disclosures of innovative small molecules and biologics that have recently entered phase I clinical trials.
The presentation will be a part of the Session VPO.CT07.02 – Phase II Trials in Progress and the abstract is number 10343.

The presentation will be at available from 9:00 a.m. - 6:00 p.m. (U.S. EDT).

The abstract will be posted online at the AACR webpage at 12:01 a.m. EDT (U.S.) on Monday, April 27.

The Virtual Meeting will be available free to everyone, although attendees will be asked to register to participate.

Registration here: https://www.aacr.org/meeting/aacr-annual-meeting-2020/coronavirus-information/

About Us

Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing one of the most important challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer drug. The Company’s leading candidate drug, SCO-101, is now ready for phase II testing in patients with drug resistant cancer disease.

Subscribe